Mounjaro prices hike sees patients switch to cheaper Wegovy
There has also been issues with some pharmacies running out of stock of Moumjaro, as patients try to get supplies before the price hike.
Mounjaro users report surprising side effect - pharmacists share their tips https://t.co/JecEW84Ifj — Bucks Free Press (@bucksfreepress) August 8, 2025
'With Mounjaro's price rise looming, it's not surprising that patients are exploring alternatives," says Jason Murphy, Head of Pharmacy at Chemist4U.
"Wegovy offers a safe, less expensive and almost equally effective weight loss solution and is a very good option to consider if Mounjaro becomes unaffordable.
'However, switching should always be as part of a conversation with your pharmacist or GP. Our role is to guide patients through the process, tailoring advice to their health history, so they can continue their weight loss journey with confidence.'
Both medications are part of a group called GLP-1 receptor agonists
What is Wegovy? Is it the same as Ozempic?
Wegovy and Mounjaro are both weekly injections originally designed for type 2 diabetes but are powerful weight-loss drugs. Wegovy (the brand name for semaglutide) works by mimicking a gut hormone (GLP-1) that curbs appetite and slows digestion. Semaglutide is also branded as Ozempic for managing type 2 diabetes, but is not prescribed for weight-loss in the UK.
Mounjaro goes a step further by also targeting a second hormone, GIP.
'When moving from Mounjaro to Wegovy, it's not a one-size-fits-all process," says Jason.
"Your starting Wegovy dose should always reflect the Mounjaro dose you were previously on, alongside your overall health, and how well you tolerated treatment. That's why a pharmacist's review is essential; it ensures the transition is safe, effective, and tailored to your individual needs.'
Who is eligible for Wegovy?
For those who have not taken a weight loss injection before, Wegovy has the same eligibility criteria as Mounjaro.
This means a BMI of 30 or higher, or a BMI of 27 or higher with a pre-existing medical condition that is affected by weight (e.g., cardiovascular disease or high blood pressure).
This might be more complicated for patients who have already lost weight on Mounjaro and are now below a BMI of 30, or 27, and now looking to continue their weight-loss, but experts recommend speaking a doctor or pharmacist.
How do you switch from Mounjaro to Wegovy?
Jason says that when switching, it's important to not stop Mounjaro until your prescriber confirms the switch to Wegovy is possible.
But, he cautions: 'Please note that the manufacturer recommends leaving 30 days from your last dose of Mounjaro and your first dose of Wegovy, to further reduce the risk of side effects, however we understand this could result in stalling your weight loss journey or potential weight gain.'
He adds that if you've already lost weight while taking Mounjaro, or are using it to maintain your weight, and are now below the eligibility criteria, you may still be able to switch to Wegovy; a clinical team will review your medical history and decide if it's safe and suitable.
Recommended reading:
What are the Wegovy and Mounjaro side effects?
People respond to medications in different ways, and even though Mounjaro and Wegovy share similar ingredients, some people may tolerate one better than another.
Jason adds: 'There are no 'withdrawal' symptoms in the usual sense. Some people notice their appetite increases as the medicine wears off, and any side effects usually settle after stopping. If you feel unwell or are unsure what to expect, speak to your prescriber.
'It's unlikely you'll gain weight when switching, as the effects of Mounjaro will continue during the seven days after your final dose. You will then immediately start taking Wegovy, which will continue to work in the same way. This means you can continue losing weight while switching, especially if you're sticking to your diet and exercise plan.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Weight loss jabs like Mounjaro linked to 'silent cancer' that is surging in under-50s, warn experts: 'We need to find out more'
Weight-loss jabs may raise the risk of kidney cancer—a 'silent killer' now striking more under-50s—even as new research suggests they could protect against other tumours. The alarm comes from the biggest study yet of patients on slimming injections such as Ozempic and Mounjaro, which tracked nearly 44,000 overweight and obese people for up to ten years. While the drugs were linked to a 17 per cent lower risk of cancer overall—with big drops in ovarian and womb tumours—researchers also uncovered a disturbing signal for kidney cancer. Patients on the jabs were about a third more likely to develop the disease than those who did not take them, with the risk highest among the under-65s and people who were overweight. Kidney cancer is one of the fastest-rising cancers in Britain and the US and is often dubbed a 'silent killer' because it rarely causes symptoms until it is advanced. Doctors warn that by the time tell-tale signs such as blood in the urine, persistent back pain or a lump under the ribs appear, it is often too late for successful treatment. Almost 14,000 Britons are diagnosed every year, with 4,700 deaths. In the US, there are around 80,000 new cases annually. If spotted early, three-quarters of patients survive at least five years – but once the cancer has spread, survival drops to just 18 per cent. Cases are also climbing sharply in younger adults. People born in 1990 are up to three times more likely to develop the disease than those born in the 1950s—a trend doctors say is partly driven by rising obesity and high blood pressure. The study, published in JAMA Oncology, compared 43,317 people prescribed the jabs with 43,315 who did not take them. In total, 891 cancers were diagnosed among jab users compared with 1,022 in non-users. But for kidney cancer there were 83 cases among users compared with 58 among non-users. Dr Hao Dai, a health data scientist at Indiana University who led the research, also expressed concern about the uptick in kidney cancer among users. 'We need to do another observational study to confirm that these drugs increase the risk,' he said. 'But from my point of view, it might be that the drugs raise the risk of some types of kidney cancer. 'We don't know, however, and need to do more research.' One theory is that the drug's common side effects, including severe nausea, vomiting, and dehydration, may trigger repeated bouts of acute kidney injury. Over time, that stress could damage kidney tissue and increase the risk of mutations that lead to cancer. Another area of concern is that the kidneys contain GLP-1 receptors. These are the same receptors Ozempic targets to regulate blood sugar and keep people full. Some scientists wonder whether constantly stimulating these receptors could cause cells in the kidneys to grow out of control, though this remains speculative and has not been proven in humans. Rapid weight loss and dramatic metabolic shifts caused by the drug might also play a role, potentially altering the body's immune response or revealing preexisting kidney issues. However Professor Paul Pharoah, a cancer specialist at Cedars-Sinai Medical Center in Los Angeles, urged caution over the findings. He said: 'While these results suggest that GLP1 receptor agonist have an effect on cancer risk the presence of an association does not mean that the association is a causal one.' Dr Stephen Lawrence, associate clinical professor at the University of Warwick, added: 'There was a slight uptick among users—two cases per 1,000 patients per year compared with 1.3 per 1,000 for non-users. 'That's about six extra cases for every 10,000 patients treated over a year. Not ideal, but still a drop in the ocean against other health benefits.' He added: 'Further research is needed before drawing any firm conclusions. The science is promising, but more research will be important to confirm these findings as more individuals begin these treatments.' At the same time, scientists found people on the jabs were significantly less likely to be diagnosed with other cancers. Rates of ovarian cancer fell by nearly half, while cases of womb cancer and certain brain tumours (meningiomas) also dropped. Overall, patients on the injections had a 17 per cent lower chance of developing cancer of any type compared with those who did not take them. The study was presented at the American Clinical Society of Oncology's annual conference in Chicago, Illinois, the largest cancer conference in the world. But experts remain cautious about over-interpreting the data, stating that the drop in cancer risk might simply be a result of weight loss itself, rather than the drugs. Slimming jabs have already been credited with cutting the risk of heart attacks, strokes and kidney failure, on top of their dramatic weight-loss effects. Experts say the latest results underline that while they may offer protection against some cancers, vigilance is still needed over the warning signs for kidney disease.
Scottish Sun
4 hours ago
- Scottish Sun
Fat jabs reduce the risk of cancer by 17% in overweight and obese people – except one, warn scientists
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WEIGHT loss jabs could lower the risk of cancer, scientists say. They found GLP-1s like Ozempic and Mounjaro reduced the overall chances of the disease by 17 per cent in overweight and obese patients. Sign up for Scottish Sun newsletter Sign up 2 Medication like Mounjaro could help people lose weight and lower their risk of cancer Credit: Getty The decreased risk was strongest for ovarian, womb and certain brain tumours. But people taking the jabs were still less likely to develop other types, including pancreatic, bladder and breast cancer, than those not on the medication. It's another breakthrough for the 'miracle' injections, which have already been shown to tackle type 2 diabetes, heart disease, stroke and possibly dementia. Author Dr Jiang Bian, from the Indiana University School of Medicine, said: 'GLP-1s are widely prescribed for glycemic control in type 2 diabetes and have recently gained popularity for weight management. 'We found they were associated with a reduced overall risk of cancer. 'Even modest changes in cancer risk could have substantial public health implications.' However, researchers also found that taking so-called 'fat jabs', which mimic a hormone to make users feel full, might be associated with an increased risk of kidney cancer, especially among users under 65. 'Further research is needed to clarify this potential risk,' Dr Bian said. The study, published in the journal JAMA Oncology, couldn't conclude whether the change in cancer risk over eight years was due to the jabs themselves or drug-induced weight loss. But scientists reckon that lower body fat, improved insulin sensitivity and reduced inflammation could be to thank. Don't fall for fake Mounjaro scams to save money on fat jab - it put me in a 'coma' & I'm still suffering, says Aisleyne Horgan-Wallace In trials, semaglutide (sold as Ozempic and Wegovy) helped users lose around 15 per cent of their body weight in 68 weeks, while those on tirzepatide (Mounjaro) shed up to 21 per cent. Dr Stephen Lawrence, associate clinical professor at the University of Warwick, who was not involved in the study, said: 'These drugs not only help shed pounds and lower blood sugar, but might add a modest bonus by being slightly associated with reducing overall cancer risk, especially for specific women's cancers. 'With millions now eligible for GLP-1 therapy, even small shifts in risk matter at scale. 'These medicines remain widely safe, with a reassuring cancer profile and only a whisper of concern about an associated increase in kidney cancer.' 2
Metro
5 hours ago
- Metro
'Ozempic vagina' is here and women are paying £2,000 to reverse it
These days you can get filler just about anywhere: your under-eyes, cheekbones, nose, and of course lips — and not just the ones on your face. That's right, people are now getting filler in their vulvas, thanks to the increasingly-popular practice of labia puffing. While the cosmetic procedure has been around since the mid-2000s, it's recently become a hot topic due to the emergence of 'Ozempic vagina' or 'Ozempic vagina'. Women taking the weight-loss drug, as well as other brands including Mounjaro and Wegovy, have reported changes in their vulvas as a result of dramatic weight loss. Plastic surgeon, Dan Marsh, tells Metro: 'When you have a lot of fat loss, the labia becomes empty and stretched, much like when people lose weight and are left with excess skin. 'It's causing an increase in patients seeking ways to fix issues of excess skin, especially over the last 12 months.' Consultant obstetrician and gynaecologist for The Portland Hospital Dr Shazia Malik tells Metro: 'Labia puffing uses dermal fillers, like hyaluronic acid or fat, to restore volume to the labia majora (the outer lips of the vulva). 'The minimally invasive procedure is designed to enhance appearance by increasing fullness, smoothness, and symmetry.' Podcast hosts Caitlin and Emily recently discussed the procedure on their podcast, The Weekly Breakdown, back in December, both claiming that they wanted a 'puffy p***y'. But let's be real, there's a serious reason some of us want to alter how our vulvas look. 'The procedure is most sought after by women looking to regain a youthful, fuller appearance due to age, weight loss, or childbirth,' Dr Malik explains. All three of the above can cause the labia to look more deflated or 'saggy' which can, understandably, lead to insecurity for some. 'Many women seek the procedure to address perceived imperfections or asymmetry,' she adds. 'Aside from aesthetic improvement, labia puffing can also increase confidence, particularly in intimate situations.' Chafing is another problem which can cause discomfort, and can also be a factor into the decision to get one's labia puffed. But others choose to have work done simply due to general self-consciousness about their genitalia's appearance, which isn't exactly surprising given how social media and porn contribute to unrealistic body standards. The Centre for Surgery, an aesthetic surgery based in London claimed labia puffing as 'contributing to a more aesthetically pleasing and youthful appearance'. It's a nod to the age-old idea that a woman's greatest pursuit is to look as young as possible, with a plump vagina seen as the latest accessory for those wanting to remain ageless. But proving that body insecurity defies generations, a University of Melbourne study that found girls as young as 13 were already worried about how their vaginas look. 'There is no 'perfect' or 'ideal' appearance for genitalia—just as with any other body part, every vagina is unique,' says Dr Malik. 'Most concerns about vaginal appearance stem from societal pressures and misinformation, not actual issues.' She warns that while discomfort or health concerns should be addressed with medical professionals, 'cosmetic procedures should only be pursued if they are personally desired.' 'Labia puffing is a personal choice, and like any cosmetic procedure, it should be approached with careful consideration,' Dr Malik adds. 'While it can offer aesthetic benefits and boost confidence, it's important you seek procedures for your own reasons and not because of societal pressures or unrealistic expectations.' The Weekly Breakdown's Catilin echoed this sentiment, saying: 'I'm all for any kind of modification, as long as it's coming from a place of 'for me'.' The obvious benefit to labia puffing, as Dr Malik points out, is the restoration of the labia majora's appearance, giving it a plumper and more youthful look. It's also non-invasive, typically carried out with local anaesthetic and carrying fewer risks than surgical alternatives like labiaplasty, along with having a shorter recovery time. But just because it has fewer risks, doesn't mean they're non-existent, and it helps to have all the facts before you cosmetically alter your body. Dr Malik says: 'The most common risks include swelling, bruising, and irritation at the injection site. Allergic reactions to the filler material, though rare, can also happen, and some patients may generally experience mild discomfort.' It's vital to make sure you're going to a reputable surgeon too, because there is a chance of uneven results or asymmetry if the procedure isn't done right. Additionally, overfilling can result in an exaggerated look, which you most likely don't want. Even if it all goes to plan, Dr Malik adds: 'In some cases the filler material could shift or form lumps, leading to an unnatural appearance. There are some more serious complications like infection or damage to surrounding tissues too, but choosing a qualified practitioner can help minimise these risks.' When Jill Lissner was just 15 years old, she went to the doctor, asking to have labiaplasty, a procedure which aims to reduce the size of the labia minora. For those who need a refresher: the labia minora are the inner lips of the vagina (they begin at your clitoris and end under the opening to your vagina). They come in all shapes and sizes, and there is literally no such thing as a 'normal' vagina, or labia, for that matter. Jill, 25, told 'Going through puberty, I noticed that one side grew, and the other didn't. It just felt different. 'I was convinced men were not going to like this on me. I thought: 'Are other people going to find this weird?' '[My mum] told me there's no such thing as normal. She explained that my vulva was going to change too, especially if I decided to have children and give birth – it's going to be ever-changing.' After discovering that her sexual partners couldn't care less what her vagina looked like, Jill's confidence blossomed and she knew she didn't need surgery. It was a long journey to self-acceptance, but Jill is no longer ashamed. She embraces her vulva and even runs a popular popular sex education Instagram page, to encourage others to do the same. There's been huge amounts of interest in labia puffing recently, with cosmetic surgeon Gerard Lambe from Reflect Clinic seeing a 20% spike in enquiries about the procedure. 'In fact, demand for labia procedures as a whole are on an upwards trend,' he tells Metro. 'We've carried out more than ever in the last few years. 'I performed 42 labia puffing procedures last year and most of these were an additional aesthetic request to a labiaplasty, but increasingly many women simply desire the filler option of a puffing procedure on its own.' According to Dr Lambe, 'very few opt for labia puffing out of pure vanity or societal pressures to have a perfect vagina.' In fact, in his opinion, 'Most women simply want to feel better in their skin and to solve what may have been an excruciatingly embarrassing issue for years – perhaps from childbirth or the menopause when tissue plumpness and elasticity decreases due to hormones.' 'I vet and appraise all patients to make sure they are emotionally and psychologically in a happy, healthy balanced state of mind before any procedure,' the surgeon adds. More Trending 'Most women tell me they're opting for the procedure to feel physically better and more comfortable, not to please a partner.' When it comes to costs, Dr Lambe explains he charges up to £500 per ml of filler, so the total cost depends on the amount of filler required. 'The first ever procedure starts with smaller amounts so that a top up is possible,' he explains. 'If puffing is combined with a labiaplasty, that can cost in the region £2,000 to £4,500. View More » Both Dr Lambe and Dr Malik urge people to do their research before undergoing the treatment and choosing a practitioner, with the former warning: 'Don't be tempted by low cost offers as these may not include consultations or follow-up care.' Do you have a story to share? Get in touch by emailing MetroLifestyleTeam@ MORE: Child bodybuilder 'Little Hercules' went viral in the 90s – but what is doing now? MORE: I'm 74 but feel 40 because of my once-a-week expense MORE: Four words that will instantly annoy your partner — no matter how well-intentioned Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
